Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2020-2031

Amyotrophic lateral sclerosis is the most common degenerative disease of the motor neuron system, enables destroy nerve cells and causes disability. Amyotrophic lateral sclerosis is known as Lou Gehrings disease. Amyotrophic lateral sclerosis often begins with muscle twitching and weakness in a limb, or slurred speech. Afterwards, may affects the control of the muscles involved in movement, speaking, eating and breathing. There is no cure for the disease and eventually disease is fatal.

The disease is inherited in 5% to 10% of cases and rest is unknown etiology. Researchers are studying several possible causes including gene mutation, chemical imbalance, and protein mishandling and disorganized immune response.Amyotrophic lateral sclerosis is difficult to diagnose, because it mimics various neurological disease symptoms. Generally ALS diagnosed using electromyogram, nerve conduction study, MRI, spinal tap and muscle biopsy. Blood and urine test are performed to sort out the other possible signs and symptoms. Two FDA approved drugs are available in the market, namely Riluzole and endaravone. Various therapies are available to reduce the symptoms of the disease.

 Key Developments:

Most of the pipeline drugs for treatment of amyotrophic lateral sclerosis pipeline are at preclinical stages. Companies with pipeline molecules mostly focused on neuroprotection, immunomodulation,andglutamate excitotoxicity blockers for the treatment of amyotrophic lateral sclerosis.

• In November 2017, U.S. Food and Drug Administration has given clearance of the clinical investigation of Biohaven Pharmaceuticals sublingual lead, BHV-0223 for the treatment of amyotrophic lateral sclerosis.
• In September 2017, U.S. Food and Drug Administration granted orphan drug designation to Revalesios investigational drug RNS60 to treat Amyotrophic Lateral Sclerosis (ALS).